Clinical Trial Update: Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail [Phase 3]

View source ↗

Summary

Pfizer-sponsored Phase 3 trial evaluating the efficacy and safety of AN2690 topical solution (tavaborole) for toenail onychomycosis has completed, with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Onychomycosis

Drugs mentioned

• Kerydin (Tavaborole)
• Tavaborole (Tavaborole)

Snippet

Sponsor: Pfizer | Conditions: Onychomycosis of Toenails | Phase 3 | Status: COMPLETED | Results posted: 2014-08-15